Abstract
Aberrant expression of wild-type and mutant forms of the platelet-derived growth factor receptor (PDGFR) family of receptor tyrosine kinases has been implicated in various oncologic indications such as leukemias, gliomas, and soft tissue sarcomas. Clinically used kinase inhibitors imatinib and sunitinib are potent inhibitors of wild-type PDGFR family members, but show reduced binding to mutant forms. Here we describe compound 5 which binds to both wild-type and oncogenic mutant forms of PDGFR family members, and demonstrates both cellular and in vivo activity.
Keywords:
Cancer; KIT; Kinase inhibitor; PDGFR; Systemic mastocytosis.
Copyright © 2018 Elsevier Ltd. All rights reserved.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Cell Line, Tumor
-
Cell Survival / drug effects
-
Dose-Response Relationship, Drug
-
Hair / drug effects
-
Hair / growth & development
-
Humans
-
Mice
-
Molecular Docking Simulation
-
Molecular Structure
-
Mutation
-
Phosphorylation / drug effects
-
Platelet-Derived Growth Factor / chemical synthesis
-
Platelet-Derived Growth Factor / chemistry
-
Platelet-Derived Growth Factor / pharmacology*
-
Protein Kinase Inhibitors / chemical synthesis
-
Protein Kinase Inhibitors / chemistry
-
Protein Kinase Inhibitors / pharmacology*
-
Receptor Protein-Tyrosine Kinases / antagonists & inhibitors*
-
Receptor Protein-Tyrosine Kinases / genetics
-
Receptor Protein-Tyrosine Kinases / metabolism
-
STAT3 Transcription Factor / antagonists & inhibitors
-
STAT3 Transcription Factor / metabolism
-
Structure-Activity Relationship
Substances
-
Platelet-Derived Growth Factor
-
Protein Kinase Inhibitors
-
STAT3 Transcription Factor
-
Stat3 protein, mouse
-
Receptor Protein-Tyrosine Kinases